Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
BörsenkürzelACON
Name des UnternehmensAclarion Inc
IPO-datumApr 22, 2022
CEOMr. Brent Ness
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeApr 22
Addresse8181 Arista Place
StadtBROOMFIELD
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl80021
Telefon18332752266
Websitehttps://aclarion.com/
BörsenkürzelACON
IPO-datumApr 22, 2022
CEOMr. Brent Ness
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten